Peptidepedia Survey 2026: Sourcing Data

About the Survey

In late 2025 and early 2026, Peptidepedia — an independent peptide information site — ran an opt-in survey on its own website. The headline result, summarised publicly on May 18, 2026, was 1,000+ completed responses across questions covering sourcing channel, monthly spend, age, gender, industry, peptide class, stacking behaviour, and self-rated outcomes.

This is not a clinical study. It is a self-selected online survey of people who already had enough interest in peptides to find Peptidepedia and finish the questionnaire. That has predictable consequences for the data:

• Selection bias is heavy. Respondents skew toward engaged, current users.
• All outcomes are self-reported. There are no verified labs, biomarkers, or controls.
• Heavy users are likely over-represented. The casual or one-time user is under-counted.

Read with those caveats in mind, the survey is best treated as a market-state snapshot of the engaged peptide user base in 2026 — not as evidence about whether or how well any specific compound works in a general population.

Finding 1: Grey Market Peptides Dominate — 70% of Users Source From RUO Suppliers

The clearest result in the dataset is also the most consequential. Seven in ten respondents reported buying grey market peptides — product sold under a “Research Use Only” label rather than through a prescription pathway. Only about one in five users went through any kind of doctor. The gray market is not a transition state in this data; it is the primary distribution channel.

Finding 2: Annual Spend Reaches $12,000+

Spending is concentrated. The median respondent spent $100–$249 a month — consistent with a single GLP-1 product cycled monthly — but the top of the distribution is steep. Roughly 11% reported $1,000+ a month, which annualises to $12,000 or more per user. That puts the heavy-user cohort in territory normally reserved for private school tuition or a paid-off car payment.

Finding 3: Tech Leads Industry Adoption

The industry breakdown reads like a chart of who has both disposable income and an information-dense relationship with their own bodies. Tech sits at the top by a clear margin; healthcare and biotech follow, which suggests a domain-knowledge effect; construction lands surprisingly high, which is harder to explain from the public data alone.

Finding 4: Stacks Beat Singles on Self-Rated Effectiveness

Respondents using a single peptide rated their experience at 2.0/4 (“somewhat effective”). Respondents stacking three or more compounds rated theirs at 3.2/4 (“life-changing”). That is a 60% jump on a self-rating scale, and it is the survey’s most actionable behavioural pattern.

Two readings are possible and both probably matter. Stack composition genuinely produces better self-perceived results — users layering, say, a GLP-1 with a recovery peptide and a sleep peptide are addressing more pain points and report a larger total effect. Or the higher self-rating is partly a commitment effect — people who have invested in a three-product stack are more invested in believing it worked. Both can be true at once. The survey can’t separate them.

What it does tell suppliers and content creators is that the question buyers are actually trying to answer is rarely “what does this single peptide do.” It is “what do I combine it with.” A single-product framing leaves most of the user’s real decision unaddressed.

Finding 5: Longevity Peptides Are Already 47% of the Market

The expected number is the GLP-1 share: 72% of respondents reported using a GLP-1 receptor agonist — semaglutide, tirzepatide, or retatrutide. That tracks with the broader GLP-1 boom and matches what we see in inbound traffic on this site.

The unexpected number is the longevity-peptide share: 47% of respondents report using compounds in the longevity category (Epitalon, MOTS-C, and similar). That is larger than TB-500, larger than growth hormone secretagogues, and roughly two-thirds the size of the GLP-1 cohort — despite carrying a fraction of the marketing budget and clinical literature behind it.

For market positioning, the implication is that the “longevity peptide” category has moved from niche to mainstream within the engaged user base. This is share of users, not share of spend, but it is enough scale to justify treating longevity as a primary category rather than a curiosity. The on-site equivalents in our catalog are MOTS-C, Epitalon, and the broader anti-aging research stack; the GLP-1 side is anchored by our Retatrutide 30mg Pen and the wider GLP-1 lineup.

Finding 6: 25–34 Is the Buying Cohort

The use-rate jump between the youngest and the second-youngest cohort is the largest single gap in the dataset. Gen Z reads about peptides; millennials buy them.

Finding 7: Use Goals Split Sharply by Gender

Weight management is the one universal use case in the sample. Beyond that, men and women report meaningfully different reasons for using peptides — large enough deltas that a category-level brand probably should not be running one undifferentiated landing page.

Finding 8: 68% Rate Their Experience as “Very Effective” or Better

Self-rated outcomes are the most caveat-heavy number in the survey, and we are surfacing the caveat first: these respondents took a peptide quiz on a peptide information site. They are not a representative sample of anyone, and the rating reflects how engaged users feel about their use, not what any peptide actually does in a controlled setting.

What the Data Tells Us About the 2026 Peptide Market

Three structural reads come out of the dataset, regardless of where the noise sits.

The gray market is structural, not transitional. 70% of demand is being filled by suppliers selling under a research-use label. That share is too large to be a regulatory waiting room. It is the dominant channel and it is likely to stay dominant until either the legal framework changes or a regulated equivalent reaches the same price point and convenience. For buyers, the practical consequence is that supplier choice matters more than category choice — verification, COA documentation, and handling discipline are the deciding factors at the point of purchase. See our buy retatrutide Dubai guide for what that verification looks like in practice.

Stacks are the unit of decision, not single compounds. Single-peptide content under-serves the buyer’s actual question. The 3+ peptide stack rating of 3.2/4 vs the single-peptide rating of 2.0/4 is the loudest behavioural signal in the survey. Coverage of any peptide that does not address what it stacks with is leaving most of the user’s decision unanswered.

Longevity is a primary category now. 47% reach inside the engaged user base is enough to treat anti-aging peptides as a category in their own right rather than a secondary line. Combined with the gender split — 75% of women report anti-aging as a goal — longevity coverage and supply is a structural opportunity for the next 12–24 months. For UAE context on the related metabolic-health side, see our obesity UAE statistics and GLP-1 landscape.

Limitations of a Self-Selected Online Survey

Every number in this article should be read against the same set of constraints. We are surfacing them in one place rather than burying them in footnotes.

• Self-selected sample. Respondents found Peptidepedia, opted in, and finished a quiz. They are not a representative slice of any defined population.
• Self-reported responses. No lab verification, no biomarker corroboration, no third-party check on what was actually used or for how long.
• No control group. Comparison to non-users or to placebo is not possible from the data.
• Heavy users over-represented. People who spend more time on peptide content are more likely to complete a peptide quiz. The casual or one-time user is systematically under-counted.
• One supplier-adjacent host. Peptidepedia is independent, but it is a peptide-focused property. A survey hosted on a general-health site would likely produce different numbers.
• Recall and framing effects. Monthly spend, stacking effectiveness, and reasons-for-use all depend on how respondents remember and frame their own behaviour.

None of these dismiss the data. They define what it is for. The survey is a directional read on engaged-user behaviour, not a clinical or market-share study. We treat it accordingly.

A Note on Research Use Only

Remy Peptides products are supplied for in-vitro laboratory research only. They are not intended for human or veterinary use, diagnosis, treatment, prevention, or cure of any condition. The survey data summarised here describes how respondents reported behaving and feeling; it is not guidance to act on. UAE customers should review MoHAP Circular 17/2022 and applicable institutional research policies before purchase. See our research standards for how we document and verify product on our side.